Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2012
Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancerFei Huang, Li-An Xu, Shirin Khambata-Ford
Personalized Medicine|May 23, 2018
The cetuximab experience: developing predictive biomarkers in oncologyChristopher T Harbison, Christine E Horak, Shirin Khambata-Ford
Cancer Cytopathology|February 8, 2018
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patientsMarius Ilie, Jonathan Juco, Lingkang Huang, et al.
Plos One|October 14, 2017
Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platformsMarius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, et al.
Plos One|August 11, 2017
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platformsMarius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, et al.
Genome Research|June 14, 2003
Identification of promoter regions in the human genome by using a retroviral plasmid library-based functional reporter gene assayShirin Khambata-Ford, Yueyi Liu, Christopher Gleason, et al.
Clinical Colorectal Cancer|August 28, 2013
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assayShao-Chun Chang, Jonathan Denne, Luping Zhao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2010
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancerShirin Khambata-Ford, Christopher T Harbison, Lowell L Hart, et al.
Archives of Pathology & Laboratory Medicine|September 19, 2024
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 StudiesZhenhao Qi, Thomas Ha, Wenqin Feng, et al.
The Journal of Molecular Diagnostics : JMD|January 29, 2025
Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02Zhenhao Qi, Shinya Tokuhiro, Justin I Odegaard, et al.
Pageof 2